News – Page 228 – Endpoints News

Ascletis’ Gannex reports positive interim PhII NASH data after scrapping previous mid-stage R&D plans

Last year

Novartis doubles down on neurologic gene therapy work with Voyager

Last year

ImmunityBio inks royalty deal, private placement to raise $210M for bladder cancer drug combo

Last year

Exclusive: Weeks after $213M launch, Tome acquires a Berkeley gene editing startup for DNA ligase technology

Last year

Verona secures $400M financing arrangement with Oxford, Hercules as ensifentrine PDUFA date inches closer

Last year

Edgewise boosts awareness of rare Becker muscular dystrophy as it pursues potential first therapy

Last year

Novartis highlights the power of language in ‘My Cancer, My Words’ campaign

Last year

Exclusive: Healthcare startup Devoted Health raises $175M

Last year

FDA seizes thousands of counterfeit Ozempic units, warns consumers not to use

Last year

Zealand drug hit with CRL for ultra-rare disease amid manufacturing concerns, plans to resubmit in 2024

Last year

Regeneron scores Eylea patent win against Mylan, keeping biosimilar at bay

Last year

IRA likely to lead to higher drug list prices and bigger rebates, Congressional Budget Office predicts

Last year

Cytokinetics' PhIII cardiomyopathy win sets up showdown with Bristol Myers and sparks M&A speculation

Last year

Theseus goes with Tang; Oncternal trial patient dies; LianBio sells drug rights to J&J

Last year

Iovance’s registrational lung cancer trial on hold after patient death

Last year

FDA declines to grant Amgen’s Lumakras full approval in lung cancer after negative advisory committee vote

Last year

Following FDA inquiry into CAR-T safety, agency adds warning on secondary cancers for Carvykti

Last year

AstraZeneca makes $1B deal for Gracell and its cell therapies, adding to China ties

Last year

J&J licenses LegoChem's Trop2 ADC for $100M upfront

Last year

Bristol Myers to buy RayzeBio for $4.1B as pharma piles into burgeoning radiopharma field

Last year

AlloVir to wind down PhIII trials for futility and will review strategic alternatives

Last year

AbbVie's $10B ImmunoGen deal was won by paying $7 a share over a rival bidder's offer, SEC filings show

Last year

Bristol Myers bets on neuroscience surge with $14B Karuna cash acquisition

Last year

FDA approves AstraZeneca, Ionis' ATTR drug as showdown with Alnylam heats up

Last year

First page Previous page 225 226 227228229 230 231 Next page Last page